title: Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.
abstract: Ischaemic heart disease (IHD) remains a major cause of morbidity/mortality globally, firmly established in Westernized or 'developed' countries and rising in prevalence in developing nations. Thus, cardioprotective therapies to limit myocardial damage with associated ischaemia-reperfusion (I-R), during infarction or surgical ischaemia, is a very important, although still elusive, clinical goal. The opioid receptor system, encompassing the δ (vas deferens), κ (ketocyclazocine) and μ (morphine) opioid receptors and their endogenous opioid ligands (endorphins, dynorphins, enkephalins), appears as a logical candidate for such exploitation. This regulatory system may orchestrate organism and organ responses to stress, induces mammalian hibernation and associated metabolic protection, triggers powerful adaptive stress resistance in response to ischaemia/hypoxia (preconditioning), and mediates cardiac benefit stemming from physical activity. In addition to direct myocardial actions, central opioid receptor signalling may also enhance the ability of the heart to withstand I-R injury. The δ- and κ-opioid receptors are strongly implicated in cardioprotection across models and species (including anti-infarct and anti-arrhythmic actions), with mixed evidence for μ opioid receptor-dependent protection in animal and human tissues. A small number of clinical trials have provided evidence of cardiac benefit from morphine or remifentanil in cardiopulmonary bypass or coronary angioplasty patients, although further trials of subtype-specific opioid receptor agonists are needed. The precise roles and utility of this GPCR family in healthy and diseased human myocardium, and in mediating central and peripheral survival responses, warrant further investigation, as do the putative negative influences of ageing, IHD co-morbidities, and relevant drugs on opioid receptor signalling and protective responses.
authors.affiliation: Heart Foundation Research Centre, Griffith Health Institute Griffith University, Southport, Qld., Australia.
authors.forename: John P
authors.initials: JP
authors.lastname: Headrick
authors.forename: Louise E
authors.initials: LE
authors.lastname: See Hoe
authors.forename: Eugene F
authors.initials: EF
authors.lastname: Du Toit
authors.forename: Jason N
authors.initials: JN
authors.lastname: Peart
mesh_terms: D000375:Aging / Q000378:metabolism; D000701:Analgesics, Opioid / Q000378:metabolism; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D009203:Myocardial Infarction / Q000378:metabolism / Q000628:therapy; D009206:Myocardium / Q000378:metabolism*; D011957:Receptors, Opioid / Q000819:agonists / Q000378:metabolism*; D013312:Stress, Physiological
chemical_list: D000701:Analgesics, Opioid; D002316:Cardiotonic Agents; D011957:Receptors, Opioid